TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

compared the efficacy and safety of a basal-bolus insulin regimen with that of sliding-scale regular insulin (SSI) in hospitalized general medical patients with type 2 diabetes. The prospective ...

[27] We consider the use of a single-dose intravenous salbutamol bolus in the ED to be more effective in achieving earlier clinical response in a subgroup of children with acute severe asthma.

TNKase ® (tenecteplase) is the first stroke medicine approved by the FDA in nearly 30 years – – Single five-second intravenous bolus provides faster and simpler administr ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed ...